PPARG and breast carcinoma: Later, combined treatment with TRAIL and PPARγ ligands, especially 15d-PGJ2, was proposed to overcome chemoresistance in ovarian cancers for successful apoptosis induction [214]. The simultaneous activation of PPARγ and RXR has been suggested to promote apoptosis, implicating the upregulation of p53 in breast cancer cell lines [215].